08:29 AM EDT, 07/07/2025 (MT Newswires) -- Artelo Biosciences ( ARTL ) said Monday that new preclinical data showed its drug candidate ART12.11 demonstrated antidepressant-like activity and cognitive benefits in a stress-induced depression model in rats.

The company said a 28-day regimen reversed depressive behaviors and improved cognitive function, performing comparably to the selective serotonin reuptake inhibitor Sertraline in behavioral measures.

ART12.11 also restored spatial and short-term memory deficits without negatively impacting social memory, according to the company.

The company's shares were up 179% in recent premarket activity on Monday.